ArriVent Biopharma
About:
ArriVent develops pharmaceutical products to cure presently untreatable cancer.
Website: https://arrivent.com/
Top Investors: General Catalyst, HongShan, OrbiMed, Sofinnova Investments, Hillhouse Investment
Description:
ArriVent is a biopharmaceutical company developing pharmaceutical products to cure presently untreatable cancer.
Total Funding Amount:
$305M
Estimated Revenue Range:
$10M to $50M
Headquarters Location:
Pennsylvania Furnace, Pennsylvania, United States
Founded Date:
2021-01-01
Contact Email:
info(AT)arrivent.com
Founders:
Bing Yao, Stuart Lutzker
Number of Employees:
11-50
Last Funding Date:
2022-12-29
IPO Status:
Public
© 2025 bioDAO.ai